Source comparison
Thymosin Alpha-1 VIP Long COVID Research: Clinical Trial Comparison
Primary Mechanism T-cell exhaustion reversal via TLR9/dendritic cell activation Microglial M1→M2 polarisation, cerebral vasodilation Tα1 targets systemic immune dysfunction; VIP targets CNS inflammation Dosing Route Subcutaneous injection, 1.6mg twice weekly I
This comparison does not assign a generated winner or score.
- Primary Mechanism
- T-cell exhaustion reversal via TLR9/dendritic cell activation
- Microglial M1→M2 polarisation, cerebral vasodilation
- Tα1 targets systemic immune dysfunction; VIP targets CNS inflammation
- Dosing Route
- Subcutaneous injection, 1.6mg twice weekly
- Intranasal spray, 50mcg three times daily
- Tα1 requires injection skill; VIP is patient-administered
- Target Symptom Domain
- Fatigue, post-exertional malaise, immune markers
- Autonomic dysfunction, brain fog, orthostatic intolerance
- Non-overlapping symptom profiles suggest combination potential
- Interim Efficacy Signal
- 42% reduction in PD-1+ T-cells, 6.2-point fatigue improvement
- 18.3-point COMPASS-31 autonomic score reduction
- Both exceed placebo by statistically significant margins
- Storage Requirements
- 2–8°C post-reconstitution, 28-day stability
- −20°C lyophilised, 7-day stability post-reconstitution
- VIP has stricter cold-chain requirements
- Current Regulatory Status
- Not FDA-approved; available via 503B compounding
- Investigational only; no approved formulation exists
- Neither is clinically accessible outside trials